It is one of the largest private financings of an Italian company to date. The financing was co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital as well as Indaco SGR. In connection with the Series B round, Marco Dieci, Senior Advisor at CDP Venture Capital and Chief Executive Officer of Simis S.r.l., will join Genespire’s Board of Directors as the representative for CDP Venture Capital, alongside Paolo Fundarò, Founder and Managing Partner from XGEN Venture.
GENE202, the…
Read More…
Source: https://european-biotechnology.com/latest-news/genespire-raises-us52m-in-series-b-round/